This is a Plain Language Summary of Publication article (PLSP) from Future Oncology that outlines the initial results of the phase 3 PAPILLON study on patients with untreated, locally advanced or metastatic non-small-cell lung cancer (NSCLC) with EGFR Exon 20 insertion mutations. Researchers evaluated the safety and effectiveness of the bispecific antibody amivantamab (RYBREVANT®) combined with chemotherapy compared to chemotherapy alone.

Visit the site using the link to read the article.

This PLSP is based on an article called ‘Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions’  that was published in The New England Journal of Medicine.

Visit The New England Journal of Medicine site using the link to the read article.